Work

Disease-relevant autoantibodies in first episode schizophrenia

Year: 2010
Type: article
Abstract: Schizophrenia is a common, heterogenous and complex disorder with unknown aetiology [1]. There is established evidence for N-methyl-D-aspartate receptor (NMDAR) hypofunction [2] as a central component of the functional dysconnectivity that is the most accepted model for symptoms [3], and increasing evidence for potassium channel dysfunction [4]. Moreover, autoimmune mecha-nisms have been proposed, perhaps in subgroups of patients [5, 6]. In the last few years, antibodies to neuronal cell surface antigens have been identified in cases of autoimmune encephalitis that respond to immunotherapy [7, 8]. Over two-thirds of patients with NMDAR antibody encephalitis, and some with potassium channel antibody-associated limbic encephalitis, have prominent psychiatric symptoms, or may present to psychiatric services in the first instance [7, 9, 10]. The psychiatric symptoms are those seen in schizophrenia including delusions, hallucinations, and catatonic movement disorder. There is good evidence for specificity and pathogenicity of these antibodies, with absence in large numbers of healthy individuals and those with other neurological diseases [9, 11, 12]. However, there have been no cases of NMDAR or potassium channel antibodies identified in patients with purely psychiatric disorders. We hypothesized that these antibodies would be present in a proportion of patients with early schizophrenia, in the absence of overt seizures, movement disorders, or other neurological signs. Serum was obtained prospectively from a cohort (n = 46) of patients at first presentation of psychosis to an epidemiologically principled early intervention for psy-chosis service
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W1968374987
FWCI: 15.71
Cites: 14
Cited by: 343
Related to: 9